摘要
目的观察晚期和局部晚期NSCLC患者βⅢ-tubulin和p53表达情况与含紫杉醇化疗方案敏感性关系。方法北京协和医院胸外科2009年11月至2010年11月收治的33例病理学诊断的晚期和局部晚期NSCLC患者,在化疗前对肿瘤组织采用免疫组化法检测βⅢ-tubulin和p53表达情况,对所有患者选用紫杉醇+铂类或5-Fu化疗方案。结果βⅢ-tubulin(-)含紫杉醇化疗方案有效率明显高于βⅢ-tubulin(+)(72%vs0%,P=0.000371),手术率更高(36%vs0%,P=0.046)。p53表达与否对紫杉醇化疗有效率和手术率的影响无统计学差异(P=1)。βⅢ-tubulin(-)且p53(+)采用紫杉醇化疗有效率为80%(P=0.022)。结论βⅢ-tubulin和p53表达情况可作为预测含紫杉醇联合化疗方案有效性和指导患者个体化化疗的指标。
Objective To determine the relationship between βⅢ-tubulin and p53 expression levels and the sensi- tivity, of paclitaxel-based chemotherapy in advanced and local advanced NSCLC. Methods The expression of βⅢ--tu- bulin and p53 in tumor tissues was examined by immunohistochemical technique before chemotherapy in 33 patients with advanced and local advanced NSCLC between November 1, 2009 and November 31, 2010. All the patients received pa- clitaxel ＋ cisplatin （carboplatin） or 5 - FU chemotherapy. Results The response rate （RR） of chemotherapy and op- erability in the patients with 13]]I-tubulin （ - ） were much higher than those with βⅢ-tubulin （ ＋ ） （72% vs 0%, P = 000371 ; 36% vs 0%, P =0. 046）. There was no significant difference in the RR and operability between p53 （ ＋ ） and p53 （ - ） patients. RR was 80% （P =0. 022） for the pateints with βⅢ--tubulin （ - ） andP53 （ ＋ ）. Conclu- sion βⅢ--tubulin 和 p53 may be the important predictive markers for the chemosensitivity of paelitaxel-based regimen and the indicators for targeted chemotherapy of NSCLC.
出处
《癌症进展》
2011年第4期420-423,共4页
Oncology Progress
